» Articles » PMID: 24900726

Deconstruction of a Nutlin: Dissecting the Binding Determinants of a Potent Protein-protein Interaction Inhibitor

Overview
Specialty Chemistry
Date 2014 Jun 6
PMID 24900726
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Protein-protein interaction (PPI) systems represent a rich potential source of targets for drug discovery, but historically have proven to be difficult, particularly in the lead identification stage. Application of the fragment-based approach may help toward success with this target class. To provide an example toward understanding the potential issues associated with such an application, we have deconstructed one of the best established protein-protein inhibitors, the Nutlin series that inhibits the interaction between MDM2 and p53, into fragments, and surveyed the resulting binding properties using heteronuclear single quantum coherence nuclear magnetic resonance (HSQC NMR), surface plasmon resonance (SPR), and X-ray crystallography. We report the relative contributions toward binding affinity for each of the key substituents of the Nutlin molecule and show that this series could hypothetically have been discovered via a fragment approach. We find that the smallest fragment of Nutlin that retains binding accesses two subpockets of MDM2 and has a molecular weight at the high end of the range that normally defines fragments.

Citing Articles

ChemoDOTS: a web server to design chemistry-driven focused libraries.

Hoffer L, Charifi-Hoareau G, Barelier S, Betzi S, Miller T, Morelli X Nucleic Acids Res. 2024; 52(W1):W461-W468.

PMID: 38686808 PMC: 11223810. DOI: 10.1093/nar/gkae326.


Translating Senotherapeutic Interventions into the Clinic with Emerging Proteomic Technologies.

Dey A, Banarjee R, Boroumand M, Rutherford D, Strassheim Q, Nyunt T Biology (Basel). 2023; 12(10).

PMID: 37887011 PMC: 10604147. DOI: 10.3390/biology12101301.


Conformation-dependent ligand hot spots in the spliceosomal RNA helicase BRR2.

Vester K, Metz A, Huber S, Loll B, Wahl M Acta Crystallogr D Struct Biol. 2023; 79(Pt 4):304-317.

PMID: 36974964 PMC: 10071561. DOI: 10.1107/S2059798323001778.


E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology.

Michaelides I, Collie G J Med Chem. 2023; 66(5):3173-3194.

PMID: 36821822 PMC: 10009759. DOI: 10.1021/acs.jmedchem.2c01882.


Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core.

Bazanov D, Pervushin N, Savin E, Tsymliakov M, Maksutova A, Savitskaya V Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455441 PMC: 9027661. DOI: 10.3390/ph15040444.


References
1.
Wells J, McClendon C . Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007; 450(7172):1001-9. DOI: 10.1038/nature06526. View

2.
Kussie P, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine A . Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996; 274(5289):948-53. DOI: 10.1126/science.274.5289.948. View

3.
Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View

4.
Bower J, Pannifer A . Using fragment-based technologies to target protein-protein interactions. Curr Pharm Des. 2012; 18(30):4685-96. DOI: 10.2174/138161212802651689. View

5.
Williamson M . Using chemical shift perturbation to characterise ligand binding. Prog Nucl Magn Reson Spectrosc. 2013; 73:1-16. DOI: 10.1016/j.pnmrs.2013.02.001. View